By Sabela Ojea


BeiGene Ltd. said Monday that a European Medicines Agency committee has recommended granting marketing authorization for its Brukinsa drug, aimed at treating adults diagnosed with a marginal zone lymphoma.

The biotechnology company said the European Union's Committee for Medicinal Products for Human Use has a positive opinion on the Brukinsa inhibitor.

"With this positive opinion, we are one step closer to bringing forward a chemotherapy-free treatment option for this rare blood cancer," said Mehrdad Mobasher, BeiGene's chief medical officer of hematology.

Marginal zone lymphoma is a group of ultra-rare, slow growing B-cell malignancies that begin in the marginal zones of lymph tissue. BeiGene said the incidence rate is estimated to range between 20 million and 30 per million a year.


Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix


(END) Dow Jones Newswires

09-19-22 0815ET